Soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice

OBJECTIVE: Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) most often caused by de novo pathogenic variants in SCN1A. Individuals with Dravet syndrome rarely achieve seizure control and have significantly elevated risk for sudden unexplained death in epilepsy (SUDEP). He...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawkins, Nicole A., Jurado, Manuel, Thaxton, Tyler T., Duarte, Samantha E., Barse, Levi, Tatsukawa, Tetsuya, Yamakawa, Kazuhiro, Nishi, Toshiya, Kondo, Shinichi, Miyamoto, Maki, Abrahams, Brett S., During, Matthew J., Kearney, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Full‐length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291096/
https://www.ncbi.nlm.nih.gov/pubmed/34510432
http://dx.doi.org/10.1111/epi.17062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291096/
https://www.ncbi.nlm.nih.gov/pubmed/34510432
http://dx.doi.org/10.1111/epi.17062

Ejemplares similares